Want to see CH:NWRN full AI Analyst Report?

Newron Pharmaceuticals SpA (NWRN) Price & Analysis

6 Followers

NWRN Stock Chart & Stats

CHF12.60

CHF0.08(0.67%)

At close: Jul 27 4:00 PM EDT

CHF12.60

CHF0.08(0.67%)

Day’s Range― - ―

52-Week RangeCHF7.61 - CHF31.85

Previous CloseN/A

Volume17.83K

Average Volume (3M)71.52K

Market Cap

CHF172.88M

Enterprise ValueCHF273.34

Total Cash (Recent Filing)CHF32.99M

Total Debt (Recent Filing)CHF39.16M

Price to Earnings (P/E)―

Beta1.97

Next Earnings

Mar 16, 2027

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.46

Shares Outstanding21,238,867

10 Day Avg. Volume128,488

30 Day Avg. Volume71,519

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)-45.95

Price to Sales (P/S)26.73

P/FCF Ratio15.73

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF44.00

Price Target Upside249.21% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-1.22

Revenue Forecast (FY)CHF11.93M

Bulls Say, Bears Say

Bulls Say

Partner Funding And Liquidity RunwayThe Eisai relationship provides external validation and meaningful funding for development, while deferred EIB repayments reduce near-term cash pressure. This combination improves the company’s ability to reach pivotal readouts and sustain operations through late 2027, subject to trial outcomes.

Large Global Pivotal Clinical ProgramA broad, global pivotal program creates several clinical catalysts and supports a clearer regulatory path for evenamide. If results confirm earlier signals, the scale of the program could strengthen partnering leverage, broaden commercial relevance, and support a potential NDA filing in 2027.

Strengthened Intellectual Property ProtectionLonger exclusivity would increase the potential commercial life of evenamide and improve the economics of future commercialization or licensing. The granted European patent already strengthens protection, while a U.S. grant could provide a durable competitive advantage beyond the current patent coverage.

Bears Say

Negative Equity And Extreme LeverageNegative equity and substantial leverage leave Newron with limited balance-sheet flexibility as it funds expensive clinical development. This increases refinancing and dilution risk, and could constrain strategic choices if pivotal results or partnering proceeds do not arrive as planned.

Volatile Revenue And Recurring LossesThe sharp reversal shows that reported revenue and profitability depend heavily on episodic licensing and milestone income rather than a stable recurring base. Persistent losses can increase financing needs and make long-term cash generation difficult until a product reaches durable commercialization.

Clinical Execution And Funding DependencyDelayed site activation and difficult recruitment could push out pivotal timelines, regulatory milestones, and potential revenue events. Because part of the planned funding depends on positive results, execution delays or weaker outcomes could shorten runway and increase the need for additional capital.

Newron Pharmaceuticals SpA News

Newron Faces Ongoing FDA Hold on U.S. Arm of Key Evenamide Schizophrenia Trial

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has shared an announcement. Newron Pharmaceuticals reported that recruitment of new patients...

6d ago

Newron Bolsters Finances as Evenamide Phase 3 Program Advances Toward 2027 Readouts

The latest update is out from Newron Pharmaceuticals SpA ( ($CH:NWRN) ). Newron Pharmaceuticals reported its 2026 half-year...

10d ago

Newron Ramps Up Evenamide Phase 3 as Financing and Patent Wins Offset Wider Loss

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an update. Newron Pharmaceuticals reported first-half 2026 results showing a...

10d ago

Newron secures EUR 5.5 million tranche to fund Phase 3 Evenamide program

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) just unveiled an update. Newron Pharmaceuticals has secured a second tranche of...

24d ago

Newron Bolsters Phase 3 Schizophrenia Program with EUR 5.5 Million Share Subscription

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an announcement. Newron Pharmaceuticals, a neuroscience-focused biopharmaceutical group based near...

24d ago

Newron completes pivotal Phase 3 recruitment for Evenamide in treatment-resistant schizophrenia

The latest announcement is out from Newron Pharmaceuticals SpA ( ($CH:NWRN) ). Newron Pharmaceuticals has completed screening for...

30d ago

Newron Advances Pivotal Phase 3 Trial of Schizophrenia Candidate Evenamide

An announcement from Newron Pharmaceuticals SpA ( ($CH:NWRN) ) is now available. Newron Pharmaceuticals has completed screening for...

30d ago

Newron, FDA in constructive talks over U.S. trial halt for schizophrenia drug Evenamide

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) just unveiled an update. Newron Pharmaceuticals has provided an update after a...

3M ago

Newron Pharma price target lowered to CHF 44 from CHF 48 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Newron Pharma (NWPHF) to CHF 44 from CHF 48 and...

5M ago

FDA halts U.S. recruitment in Newron’s key schizophrenia trial after patient death

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an update. Newron Pharmaceuticals said the U.S. Food and Drug...

5M ago

Newron Shareholders Back Board Changes at 2026 General Meeting

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an announcement. Newron Pharmaceuticals reported that shareholders at its 2026...

5M ago

Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 48 from...

6M ago

Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 43 from...

9M ago

Newron Pharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 73...

10M ago

NWRN FAQ

What was Newron Pharmaceuticals SpA’s price range in the past 12 months?

Newron Pharmaceuticals SpA lowest stock price was CHF7.61 and its highest was CHF31.85 in the past 12 months.

What is Newron Pharmaceuticals SpA’s market cap?

Newron Pharmaceuticals SpA’s market cap is CHF172.88M.

When is Newron Pharmaceuticals SpA’s upcoming earnings report date?

Newron Pharmaceuticals SpA’s upcoming earnings report date is Mar 16, 2027 which is in 165 days.

How were Newron Pharmaceuticals SpA’s earnings last quarter?

Newron Pharmaceuticals SpA released its earnings results on Sep 22, 2026. The company reported -CHF0.179 earnings per share for the quarter.

Is Newron Pharmaceuticals SpA overvalued?

According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA does not currently pay dividends.

What is Newron Pharmaceuticals SpA’s EPS estimate?

Newron Pharmaceuticals SpA’s EPS estimate is -0.7.

How many shares outstanding does Newron Pharmaceuticals SpA have?

Newron Pharmaceuticals SpA has 21,238,867 shares outstanding.

What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?

Newron Pharmaceuticals SpA reported an EPS of -CHF0.179 in its last earnings report. Following the earnings report the stock price went down -1.601%.

Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?

Currently, no hedge funds are holding shares in CH:NWRN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Newron Pharmaceuticals SpA

Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.

Newron Pharmaceuticals SpA (NWRN) Earnings & Revenues

Historic Earnings Reports

NWRN Stock 12 Month Forecast

Average Price Target

CHF44.00

▲(249.21% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"CHF7","26":"CHF26","45":"CHF45","16.5":"CHF16.5","35.5":"CHF35.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF44.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,16.5,26,35.5,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.18,14.627692307692307,17.075384615384614,19.52307692307692,21.97076923076923,24.418461538461536,26.866153846153846,29.313846153846153,31.76153846153846,34.20923076923077,36.65692307692308,39.104615384615386,41.55230769230769,{"y":44,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.18,14.627692307692307,17.075384615384614,19.52307692307692,21.97076923076923,24.418461538461536,26.866153846153846,29.313846153846153,31.76153846153846,34.20923076923077,36.65692307692308,39.104615384615386,41.55230769230769,{"y":44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.18,14.627692307692307,17.075384615384614,19.52307692307692,21.97076923076923,24.418461538461536,26.866153846153846,29.313846153846153,31.76153846153846,34.20923076923077,36.65692307692308,39.104615384615386,41.55230769230769,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.75,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.92,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.44,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.85,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.18,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >